

1 **Glycosylation state of vWF in circulating extracellular vesicles serves as a novel**  
2 **biomarker for predicting depression.**

3  
4 **Authors:** Norihiro Yamada<sup>1</sup>, Kana Tominaga<sup>1\*</sup>, Naoomi Tominaga<sup>2</sup>, Ayumi Kobayashi<sup>1</sup>, Chihiro  
5 Niino<sup>1</sup>, Yuta Miyagi<sup>2</sup>, Hirotaka Yamagata<sup>1,3</sup>, Shin Nakagawa<sup>1</sup>

6  
7 **Affiliations:**

8 <sup>1</sup>. Division of Neuropsychiatry, Department of Neuroscience, Yamaguchi University Graduate  
9 School of Medicine, 1-1-1 Minami-kogushi, Ube, Yamaguchi, 755-8505, Japan

10 <sup>2</sup>. Department of Laboratory Medicine, Faculty of Health Sciences, Yamaguchi University  
11 Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan

12 <sup>3</sup>. Kokoro no Hospital Machida, 2140 Kamioyamadamachi, Machida, Tokyo 194-0201, Japan

13 \* Corresponding author

14  
15 **Contact Information:**

16 Kana Tominaga, Ph.D.  
17 Division of Neuropsychiatry, Department of Neuroscience,  
18 Yamaguchi University School of Medicine  
19 [kanat@yamaguchi-u.ac.jp](mailto:kanat@yamaguchi-u.ac.jp)

20  
21 **Keywords:** Major depressive disorders, Biomarkers, Extracellular vesicles, N-linked  
22 glycosylation, von Willebrand factor

23

## 24 **Abstract**

25 The clinical diagnosis of major depressive disorder (MDD), a heterogeneous disorder, still  
26 depends on subjective information in terms of various symptoms regarding mood. Detecting  
27 extracellular vesicles (EVs) in blood may result in finding a diagnostic biomarker that reflects the  
28 depressive stage of patients with MDD. Here, we report the results on the glycosylation pattern  
29 of enriched plasma EVs from patients with MDD and age-matched healthy subjects. In this cohort,  
30 the levels of *Triticum vulgare* (wheat germ) agglutinin (WGA), *N*-acetyl glucosamine (GlcNAc)  
31 and *N*-acetylneuraminic acid (Neu5Ac, sialic acid) - binding lectin, were significantly decreased in  
32 patients with MDD in depressive state compared to healthy subjects (area under the curve (AUC):  
33 0.87 (95% confidence interval (CI) 0.76 - 0.97)) and in remission state (AUC: 0.88 (95% CI 0.72  
34 - 1.00)). Furthermore, proteome analysis revealed that the von Willebrand factor (vWF) was a  
35 significant factor recognized by WGA. WGA-binding vWF antigen differentiated patients with MDD  
36 versus healthy subjects (AUC: 0.92 (95% CI 0.82 - 1.00)) and the same patients with MDD in  
37 depressive versus remission state (AUC: 0.98 (95% CI 0.93 - 1.00)). In this study, the change  
38 patterns in the glycoproteins contained in plasma EVs support the usability of testing to identify  
39 patients who are at increased risk of depression during antidepressant treatment.

40

## 41 **Introduction**

42 Depression is a major mental health challenge globally and the leading cause of mental health-  
43 related disability worldwide (Herrman et al., 2019). Even among international consensus  
44 diagnostic criteria, such as the International Classification of Diseases 11th (ICD-11) and the  
45 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR),  
46 diagnosing depression is based on a combination of symptoms. These diagnostic methods do  
47 not include objective laboratory findings (Malhi & Mann, 2018). Diagnosis and symptom  
48 evaluation of major depressive disorder (MDD) have depended on subjective information such as

49 physicians' clinical experiences and patient self-assessments, which can unfortunately lead to  
50 misdiagnosis (Mitchell et al., 2009). Therefore, it is highly desirable to elucidate the  
51 pathophysiology of depression and discover diagnostic markers for depression that reflect the  
52 pathophysiology of depression to change this situation.

53 Extracellular vesicles (EVs) are microscale vesicles composed of lipid bilayers released by  
54 various cell types, containing proteins, nucleic acids, lipids, and metabolites (Tominaga, 2021).  
55 Since EVs are involved in intercellular signaling, as they are transported and function between  
56 host and recipient cells (Xu et al., 2016), EVs are valuable tools for studying cell-cell  
57 communication in biological processes, including cancer, autoimmune disease, and  
58 neurodegenerative disorder, leading to blood-based biomarkers for early diagnosis disease (Wu  
59 et al., 2020; Delpech et al., 2019). For a diagnosis of MDD, most preclinical studies focus on  
60 proteins and microRNAs in EVs related to metabolic pathways in the central nervous system  
61 (CNS), neuro-inflammation, and neuroplasticity in the development of MDD (Li et al, 2021; Gelle  
62 et al., 2021; Hung et al., 2021). L1 cell adhesion molecule (L1CAM/CD171) is a helpful marker  
63 protein of EVs with putative CNS neuronal origin (Goetzl et al., 2021; Saeedi et al., 2021; Nasca  
64 et al., 2021). However, recent reports have questioned L1CAM as a marker protein from brain  
65 neuronal EVs because L1CAM is ubiquitously and transiently expressed in immune cells, specific  
66 epithelial cells, endothelial cells, and neural cells (Norman et al., 2021). Moreover, since there is  
67 still no standardized extraction protocol to purify EVs from peripheral blood for a diagnosis of MDD,  
68 the abundance of EVs and key factors in EVs can make a significant difference in each experiment  
69 and across facilities.

70 Glycosylated proteins, lipids, neurotransmitters, and hormones have important roles in  
71 communicating with surrounding cells through discrimination of their biomolecules (Ohtsubo &  
72 Marth, 2006). These glycosylated molecules are promising disease biomarkers (Kronimus et al.,  
73 2023; Pradeep et al., 2023; Paton et al., 2021; Chandler & Goldman, 2013; Costa et al., 2023).

74 N-glycosylation plays a crucial role in several biological processes, especially those in the immune  
75 system. Since the onset and course of MDD are associated with alterations in the immune  
76 response, several reports have indicated that N-linked glycosylation is relevant to the diagnosis  
77 of the depressive state in women and the antidepressant treatment response in serum and  
78 plasma (Boeck et al., 2018; Park et al., 2018). We also previously reported that glycan patterns  
79 determined by lectin array in plasma obtained from depression model mice and patients with MDD  
80 and that alterations in glycosylate structures could be a diagnostic marker (Yamagata et al., 2018).  
81 EVs also have glycoproteins and glycolipids on their surface layer and inside, and this  
82 glycosylation pattern changes according to the condition depending on biological processes and  
83 diseases (Nishida-Aoki et al., 2020). However, the importance of EV glycosylation in  
84 understanding depressive status remains largely unknown.

85 Therefore, this study investigated whether the glycosylation pattern of plasma EVs between  
86 patients with MDD in depressive or remission state and healthy subjects was different.  
87 Furthermore, we revealed the glycoprotein with characteristic glycans for patients with MDD to  
88 construct a novel detection system reflected in depressive status.

89

## 90 **Materials and Methods**

### 91 **Human subjects**

92 We carried out this study following the latest version of the Declaration of Helsinki. The  
93 Institutional Review Board of Yamaguchi University Hospital approved this study (H25-085-13,  
94 H23-153-19, H2022-203), and all subjects provided written informed consent for participation. We  
95 recruited patients with MDD and healthy subjects as previously described (Yamagata et al., 2018).  
96 Briefly, patients with MDD were recruited from Yamaguchi University Hospital or referred by  
97 clinics and hospitals in the area. All subjects were recruited between April 2012 and June 2013

98 and followed until August 2014. We screened patients with MDD and diagnosed them using a  
99 structured clinical interview that included the International Neuropsychiatric Interview [M.I.N.I.],  
100 Japanese version 5.0.0 (Otsubo et al., 2005). We defined depression by a score greater than 18  
101 on the Hamilton Rating for Depression Scale (HDRS) (HAMILTON, 1960). The Global  
102 Assessment of Functioning Scale (GAF) was used to assess social functioning (Moos et al., 2000).  
103 The Mini-Mental State Examination (MMSE) was used to exclude patients with possible dementia  
104 (score < 24) (Folstein et al., 1975). We classified patients in remission following the DSM-5 criteria  
105 for full remission. Healthy subjects were recruited using advertisements in the local community  
106 and screened using the MINI and a clinical interview. Any healthy subjects with a family history of  
107 psychiatric disease were excluded from the study. The demographic data of patients with MDD  
108 and healthy subjects included in this study are summarized in Table S1.

#### 109 **Isolation of EVs from human plasma**

110 We collected venous fasting blood from subjects between 9:00 and 12:00. Blood samples were  
111 centrifuged at 2400 ×g for 5 min to separate plasma from peripheral blood cells. These samples  
112 were stored at -80 °C until we used them. 500 µL of processed plasma was directly overlaid onto  
113 qEV size exclusion columns (qEVOriginal-70 Gen2, Izon Science Ltd.), followed by sample  
114 concentration to a final volume of 400 µL. To estimate the protein concentration of each qEV  
115 fraction, we used the Micro BCA protein assay kit (Thermo Fisher Scientific Inc. MA, USA)  
116 according to the manufacturer's protocol. To confirm the fractions of concentrated EVs, we did a  
117 western blot with antibodies against CD9 and CD63 as EV markers.

#### 118 **Nanoparticle tracking analysis (NTA)**

119 We measured the size distribution and concentration of particles with Videodrop (Myriade Paris,  
120 France). 7 µL of each EV fraction was used to measure the concentration and size of particles in  
121 each condition. The threshold was set at 4.2 for the removal of macro particles, and the exposure

122 time was 0.90 ms for each frame. Accumulations were performed to count enough particles, with  
123 100 - 300 particles counted for each condition.

#### 124 **Lectin blotting**

125 EVs were denatured with lysis buffer with 2-mercaptoethanol at 99°C for 5 min. Lysates were  
126 loaded 400 ng protein per lane to run SDS-PAGE. Separated proteins were transferred to the  
127 PVDF membrane and incubated with biotinylated lectins (#BK-1000, VECTOR LABORATORIES,  
128 INC.), following Table S2. After washing, streptavidin-HRP at 1:5000 dilution was incubated at  
129 room temperature for 20 min. The membrane was developed by Immobilon Western  
130 Chemiluminescent HRP Substrate and examined using an Amasham imaging system.

#### 131 **Western blotting**

132 EVs were denatured with SDS sample buffer with 100 mM of dithiothreitol (DTT) (Nacalai Tesque,  
133 Japan) at 99 °C for 5 min (for reduced) or without DTT at 37 °C for 30 min (for non-reduced).  
134 Lysates were loaded 400 ng protein per lane to run SDS-PAGE. We separated proteins by SDS-  
135 PAGE and transferred them to polyvinylidene fluoride (PVDF) membranes. The membranes were  
136 blocked with Block Ace (Bio-rad) and incubated overnight at 4°C with primary antibodies, which  
137 included anti-CD63 (3-13, 1:1000, Wako), anti-CD9 (12A12, 1:1000, Cosmo bio), anti-cytochrome  
138 C (1:1000, proteintech), anti-vWF (EPSISR15, 1:1000, abcam). After washing PBS containing  
139 0.1% Tween 20, the membranes were incubated at room temperature for 1 hour with horseradish  
140 peroxidase (HRP)-conjugated anti-rabbit or anti-mouse IgG (CST) as secondary antibodies.  
141 Signals were developed using an Immobilon Western Chemiluminescent HRP Substrate (Cytiva)  
142 and examined using an Amasham imaging system (GE Healthcare). We used Fiji (ImageJ 1.53t)  
143 to analyze the intensity of bands.

#### 144 **Deglycosylation enzyme treatment *in vitro* for plasma EVs**

145 Plasma EVs (400 ng) of healthy subjects were treated with  $\alpha$ 2-3,6,8 Neuraminidase (Sialidase,  
146 P0720, New England BioLabs, MA, USA) at least 50 unit per sample at 37°C for 1 h. The removal  
147 of glycans under this condition was confirmed by lectin blot or ELISA. The particle tracking  
148 analysis confirmed that most EVs maintained their vesicle structures after the enzymatic digestion.

#### 149 **Enzyme-linked immuno-sorbent assay (ELISA)**

150 We equally mixed plasma EVs and M-PER (Thermo Scientific, MA, USA) to isolate proteins from  
151 plasma EVs for ELISA. We assessed samples with VWF Human ELISA Kit (#EHVWF, Invitrogen)  
152 according to the manufacturers ' instructions.

153 For constricting of the sandwich ELISA to quantify WGA-binding vWF, 96-well plates with the  
154 antibody against human vWF were treated with PNGase F (P0704, New England Biolabs, MA,  
155 USA) to remove N-linked glycan for 4 hours at 37 °C. After washing, plasma EVs were added to  
156 plates and incubated overnight at 4 °C. Plates were incubated with WGA lectin (1:1000) at room  
157 temperature for 1 hour, following diluted streptavidin-HRP room temperature for 45 min. We  
158 measured absorbance at 450 nm using a Flexstaion 3 (Molecular Devices, USA) within 30 min  
159 after adding the TMB Substrate.

#### 160 **Mass spectrometry and proteomic analysis**

161 We performed proteomic analysis as previously reported. The EV lysates were dissolved by an  
162 equal amount of M-PER buffer and suspended in SDS-PAGE sample buffer with dithiothreitol  
163 (DTT). The samples were boiled at 99 °C for 5 min and resolved by SDS-PAGE. The gel was  
164 stained using a Silver Stain KANTO III (Kanto Chemicals). After slicing the gel, sliced gels were  
165 incubated at 37°C for trypsin digestion. Recovered peptides were desalted by Ziptip c18 (Millipore).  
166 Samples were analyzed using a nanoLC/MS/MS system (DiNa HPLC system KYA TECH  
167 Corporation/QSTAR XL Applied Biosystems). Mass data acquisitions were piloted by Mascot  
168 search (MS/MS Ion Search).

169 **Transmission electron microscopy (TEM)**

170 Formvar/carbon coated copper grid (NISSIN EM co. Ltd., Japan) was hydrophilized with JFC-1600  
171 Auto Fine Coater (JEOL, Japan). 3 $\mu$ L of purified EVs in PBS were placed on the hydrophilized  
172 grid and absorbed for 3min. We washed the grid using 500  $\mu$ L double-distilled H<sub>2</sub>O successive  
173 four drops, then negatively stained using 30  $\mu$ L of 2.0% uranyl acetate successive four drops. The  
174 grid was air-dried after absorbing 2.0% uranyl acetate on the grid with filter paper. We imaged the  
175 grid with Tecnai G2 Spirit BioTWIN electron microscopy (FEI) operating 120 kV equipped with a  
176 Phurona CMOS camera (Emsis). After exporting the raw data images to TIFF format, we used  
177 Fiji (ImageJ 1.53t) for data analysis.

178 **Quantification and statistical analysis**

179 We performed the statistical analysis and visualized data using R software (v4.3.1). We used  
180 Student's t-test or Mann - Whitney U test to compare the differences between the two groups. We  
181 also used Bartlett's test and one-way ANOVA for differences between the variances of the three  
182 groups. Graphs show mean  $\pm$  standard deviation (SD). We used the pROC package (v1.18.5) in R  
183 software to estimate the prediction value for diagnosis. The area under the curve (AUC) of ROC  
184 was analyzed to judge the accuracy of the predictive model. We used the curve closest to the  
185 (0,1) to estimate the cut-off point.

186

187 **Results**

188 **Characterization of plasma EVs from patients with major depressive disorders and**  
189 **healthy subjects.**

190 Participant demographic and clinical data acquired from the experiment are shown in Table S1.  
191 Differences in age, gender, HDRS, and GAF were nonsignificant among all groups. Differences  
192 in onset age and dose of antidepressants were also nonsignificant between depressive and



193 remission states. We collected plasma EVs using qEV columns following a specific protocol (Fig.  
194 1). EVs were purified from the plasma of healthy subjects (HS, n = 20) or patients with major  
195 depressive disorder (MDD, n = 21) through the size-exclusion chromatography (SEC). To collect  
196 the EVs enriched fraction, we performed a BCA protein assay to estimate protein concentration  
197 and western blotting with antibodies against CD63 and CD9 as EV-markers. Plasma proteins  
198 eluted later fractions (F10-12) than EVs (F7-9). Since both CD63 and CD9, specific EV markers,  
199 were detected using western blotting, we used fractions 7–9 in this experiment.

200 To evaluate the characterizations of plasma EVs in depressive states, we isolated the fraction  
201 containing EVs obtained from plasma from both patients with MDD and healthy subjects by  
202 detecting the expression of the EV marker proteins, CD63 and CD9 (Fig. 2A). The purified EVs  
203 were observed by transmission electron microscopy (TEM), which showed the morphology, as  
204 commonly seen between patients with MDD and healthy subjects (Fig. 2B). Particle size  
205 distribution confirmed that the EVs from each sample population were in the range of 50 – 300  
206 nm with peaks at around 150 nm (Fig. 2C). The modal particle size and the number of EV particles  
207 were similar among the EVs from healthy subjects and those in patients with MDD (Fig. 2D). On  
208 the other hand, the amount of protein in plasma EVs from patients with MDD was significantly  
209 decreased in that of healthy subjects. When we compared the modal particle size, the number of  
210 EV particles, and protein concentration between in depressive and remission states of the same  
211 patients, there was no statistically significant (Fig. 2E). These results indicated that protein  
212 contents in plasma EVs are possible to decrease or change during the progression of depression.

213 **The extent of WGA-binding glycoprotein is reflected in the patients with MDD in a**  
214 **depressive state.**

215 To characterize EV glycosylation in patients with MDD in depressive state, we recognized glycans  
216 by lectin blotting. We summarized the glycan structures specific to each lectin in Table S2. SDS–  
217 PAGE revealed a complex mixture of proteins detected in plasma EVs when we loaded the same

218 amount of EV protein. O-type glycosylation patterns among *Ulex europaeus* agglutinin 1 (UEA-  
219 1), *Arachis hypogaea* agglutinin (PNA), and *Dolichos biflorus* agglutinin (DBA) were rarely  
220 detected in both healthy subjects and patients with MDD in depressive state (Fig. 3A). On the  
221 other hand, N-type glycosylation patterns were detected with lectins recognized by Concanavalin  
222 A (ConA), *Ricinus communis* agglutinin (RCA120), and *Triticum vulgare* (wheat germ) agglutinin  
223 (WGA), but not Soybean Agglutinin (SBA) (Fig. 3B). Significant differences observing for ConA,  
224 RCA120 and WGA between the two groups, we selected three lectins to measure the intensities  
225 of the visible bands at approximately 250 kDa. The amount of glycosylated protein with a  
226 molecular weight above 250 kDa recognized by WGA significantly decreased in plasma EVs from  
227 patients with MDD compared with healthy subjects (Fig. 3C, densitometric intensity of HS,  
228  $6221.34 \pm 1422.17$  and DP,  $2833.87 \pm 1254.72$ ;  $p = 0.00727$ ). Moreover, to validate the discovery  
229 results, we compared all participants in patients with MDD ( $n = 21$ ) and healthy subjects ( $n = 20$ ).  
230 The intensity of WGA was significantly lower in the patient with MDD than in the healthy subjects  
231 (Fig. 3D, densitometric intensity of HS,  $5162.67 \pm 3360.85$  and DP,  $1338.97 \pm 1898.61$ ;  $p =$   
232  $0.00008$ ). When we constructed a receiver operating characteristic curve (ROC) curve of relative  
233 intensity of WGA between patients with MDD in depressive state and healthy subjects, ROC  
234 analysis yielded an AUC of 0.87 (95% CI 0.76 - 0.97) (Fig. 3E), thus indicating the predictive  
235 power of plasma EVs with glycans in patients with MDD.

236 Next, to assess the diagnosis of depressive state, we compared the amount of WGA-binding  
237 protein with a molecular weight above 250 kD in plasma EVs between depressive and remission  
238 state of the same patients with MDD ( $n = 10$ ) by lectin blotting (Fig. 3F). The intensity of the protein  
239 band at a molecular weight above 250 kDa in plasma EVs from depressive state individuals  
240 detected by WGA was significantly lower than that from EVs from those that had recovered to  
241 remission state (Fig. 3G, densitometric intensity of DP,  $1390.40 \pm 1993.23$  and REM,  $4723.40 \pm$   
242  $2277.96$ ;  $p = 0.0040$ ). In addition, the ROC curve showed an AUC of 0.88 (95% CI 0.72 - 1.00)

243 for plasma EVs, which distinguished each status (Fig. 3H). We previously reported the results of  
244 a lectin array using leukocytes obtained from the human peripheral blood of patients with MDD  
245 and healthy subjects (Yamagata et al., 2018). Among them, there were no differences between  
246 the patients with MDD and healthy subjects determined by different sialic acid binding lectins,  
247 including ConA, RCA120, and WGA (Fig. S1). These data show that a decrease in glycoproteins  
248 recognized by WGA in plasma EV could indicate the status of depressive symptoms, which have  
249 the potential for diagnosis of depression.

### 250 **Proteome analysis reveals that vWF selectively contained in plasma EVs.**

251 The lectin of WGA can bind to oligosaccharides containing terminal N-acetyl glucosamine  
252 (GlcNAc) and N-acetylneuraminic acid (Neu5Ac, also known as sialic acid). To search for proteins  
253 that could link N-linked carbohydrate chains containing terminal GlcNAc and sialic acid, we first  
254 performed silver staining on samples from healthy subjects (Fig. 4A). We next analyzed the  
255 identified proteins by mass spectrometry. Among them, one of the most significant hits was the  
256 von Willebrand factor (vWF) (Fig. 4B, Fig. S2). vWF is a glycoprotein implicated in the  
257 maintenance of hemostasis at the sites of vascular injury by forming a molecular bridge between  
258 the subendothelial matrix and platelet-surface receptor complex (Peyvandi et al., 2011). We  
259 confirmed that the vWF proteins, detected by western blotting, had a molecular weight above 250  
260 kDa in plasma EVs from healthy subjects and patients with MDD (Fig. 4C). Human vWF is capped  
261 by terminal negatively charged sialic acid residues (Ward et al., 2019). After sialidase digestion  
262 *in vitro*, the levels of the vWF protein decreased and shifted to a molecular weight of less than  
263 250 kDa (Fig. 4D). Thus, our data suggested that plasma EVs contained vWF expressing terminal  
264 sialic acid.

265 To assess the expression of vWF protein in patients with MDD and healthy subjects, we  
266 performed sandwich ELISA on the vWF protein from the same amount of plasma EVs in each  
267 sample. vWF protein expression was significantly lower in plasma EVs from patients with MDD in

268 depressive state (mean concentration  $0.187 \pm 0.220$   $\mu\text{g/mL}$ ,  $n = 21$ ) than in those from healthy  
269 subjects (mean concentration  $0.376 \pm 0.143$   $\mu\text{g/mL}$ ,  $n = 20$ ) (Fig. 4E). ROC analysis of plasma  
270 EVs from patients with MDD in depressive state and healthy subjects yielded an AUC of 0.77  
271 (95% CI 0.60 – 0.93) (Fig. 4F). Furthermore, the concentration of vWF protein in plasma EVs  
272 recovered during remission status (mean concentration  $0.572 \pm 0.104$   $\mu\text{g/mL}$ ,  $n = 10$ ) (Fig. 4G).  
273 In validation, vWF protein in depressive state was distinguished from remission status by ROC  
274 (AUC of 0.87 (95% CI 0.71 - 1.00)) (Fig. 4H). Hence, these results indicate that vWF-containing  
275 plasma EVs strongly correlated with the patients with MDD in depressive state.

276 Plasma consistently contains abundant vWF because multimer vWF is essential in immediately  
277 responding to an injury (Peyvandi et al., 2011). The amount of released vWF to plasma was no  
278 significant difference between patients with MDD ( $3.979 \pm 0.683$   $\mu\text{g/mL}$ ,  $n = 10$ ) and healthy  
279 subjects ( $4.461 \pm 0.480$   $\mu\text{g/mL}$ ,  $n = 10$ ) (Fig. S3). We could confirm that the amount of vWF on  
280 plasma EVs was altered in patients with MDD compared to healthy subjects, which did not depend  
281 on the amount of vWF in plasma.

### 282 **The expression levels of WGA-vWF strongly correlate with the treatment state in patients** 283 **with MDD.**

284 To determine if plasma EVs containing WGA-binding vWF (WGA-vWF) could be applied as a  
285 diagnostic marker for MDD in the clinic, we designed a sandwich ELISA system to detect both  
286 WGA and vWF antigen in plasma EVs (Fig. 5A). The anti-vWF antibody without N-linked  
287 carbohydrate using PNGase F was immobilized on a 96-well plate. Plasma EVs were captured  
288 and detected with biotinylated WGA. The constructed standard curve exhibited concentration-  
289 dependent linearity (Fig. S4). When we also measured the absorbance of WGA-binding vWF after  
290 sialidase treatment, the absorbance was decreased compared with no treatment (Fig. 5B). Hence,  
291 the ELISA we developed was acceptable for detecting both WGA and vWF in plasma EVs.

292 When we considered whether ELISA detected WGA-vWF in plasma EVs can help diagnose  
293 depression, WGA-vWF expression was significantly lower in plasma EVs of patients with MDD in  
294 depressive state (mean concentration  $0.068 \pm 0.104$   $\mu\text{g/ml}$ ,  $n = 21$ ) than those of healthy subjects  
295 (mean concentration  $0.274 \pm 0.212$   $\mu\text{g/ml}$ ,  $n = 20$ ) (Fig. 5C). ROC analysis indicated that the AUC  
296 value for the diagnosis was 0.92 (95% CI 0.82 - 1.00) between patients with MDD and healthy  
297 subjects (Fig. 5D). Furthermore, WGA-vWF expression remarkably increased from depressive  
298 (mean concentration  $0.030 \pm 0.029$   $\mu\text{g/ml}$ ) to remission processes (mean concentration  $0.419 \pm$   
299  $0.260$   $\mu\text{g/ml}$ ) (Fig. 5E). We also could distinguish between patients with MDD in depressive and  
300 remission states (AUC of 0.98, 95% CI 0.93 - 1.00) (Fig. 5F). This ELISA combines WGA and  
301 vWF is more specific method than ELISA using the vWF antibody alone. Our findings suggested  
302 that WGA-vWF is a potential biomarker for the diagnosis of patients with MDD in depressive state.

303

## 304 Discussion

305 In this study, we investigated the glycans on circulating EVs as potential signatures in patients  
306 with MDD and healthy subjects by lectin blotting. We found that the levels of *Triticum vulgare*  
307 agglutinin (WGA), a lectin for terminal N-acetylglucosamine (GlcNAc) and N-acetylneuraminic  
308 acid (Neu5Ac, sialic acid), could distinguish not only between patients with MDD and healthy  
309 subjects but between patients with MDD in depressive state and remission. Additionally, we show  
310 that vWF containing sialic acid from circulating EVs in peripheral blood is a biomarker of patients  
311 with MDD. To our knowledge, this is the first report on a biomarker using EVs containing a  
312 glycoprotein that reflects the state of patients with MDD.

313 vWF is a large multidomain protein consisting of type A and D domains that can interact with  
314 multiple proteins (Gogia & Neelamegham, 2015; Denorme et al., 2019). vWF is mainly produced  
315 in endothelial cells and megakaryocytes, which are present in blood plasma (Leebeek &  
316 Eikenboom, 2016). vWF plays an important role in blocking blood vessels from binding to platelets

317 via platelet receptors and aggregates after vascular injury (Bockenstedt et al., 1986; Ju et al.,  
318 2015; Bonazza et al., 2022). Multimer vWF builds in the Golgi complex and is stored within the  
319 Weibel-Palade body (WPB), similar to storage granules after being transported within lipid  
320 bilayers (Valentijn et al., 2008). vWF colocalizes with CD63, one of the specific EV markers, in  
321 the WPB of endothelial cells and is often associated with internal vesicles (Streetley et al., 2019).  
322 Accordingly, vWF may exist on EV surfaces, except for an adhesive surface or WPB on activated  
323 endothelial cells. Another group reported that vWF in plasma EVs obtained from patients with  
324 glioblastoma is a biomarker that might assist in diagnosing and managing glioblastoma (Sabbagh  
325 et al., 2021).

326 It is essential to determine whether vWF expression is the cause or origin of MDD symptoms in  
327 patients with MDD. Chronic stress leads to a tightly controlled process that involves a wide array  
328 of neuronal and endocrine systems (Smith & Vale, 2006). Depressed patients have hyperactivity  
329 of the hypothalamic-pituitary-adrenal axis (HPA) and high levels of glucocorticoids (GCs), which  
330 are secreted from the adrenal glands. The feedback to the brain, damages the portions of the  
331 brain environment, such as the hippocampus, resulting in a depressed mood (Ignácio et al., 2019).  
332 GCs bind to the promoter region of vWF and promote vWF expression, indicating a positive  
333 correlation between GC and vWF expression in Cushing syndrome patients (Casonato et al.,  
334 2008). Therefore, since vWF expression in plasma EVs significantly decreased in patients with  
335 MDD in depressive state, vWF does not appear to be downstream of the HPA system.  
336 Inflammation can also alter the brain signaling system through the CNS (Steinmetz & Turrigiano,  
337 2010). Inflammatory cytokines, such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin-1 beta (IL1 $\beta$ ),  
338 and interleukin-6 (IL6), are secreted by microglia, which control the immune system in the brain  
339 (Steinmetz & Turrigiano, 2010; Zhu et al., 2006; Recasens et al., 2021) and activate serotonin  
340 transporters (Baganz & Blakely, 2013). Depressed patients have high expression levels of stress-  
341 induced inflammatory cytokines (Uddin et al., 2011). Multimer vWF secretion is high during

342 inflammation associated with thrombus formation after vascular injury(B. Boneu et al., 1975), but  
343 vWF expression in vascular endothelial cells is decreased by TNF- $\alpha$  treatment in vitro (Li et al.,  
344 2015). Therefore, vWF expression in vascular endothelial cells may be downregulated by a stress  
345 response through an inflammatory pathway, leading to EV secretion with low levels of vWF from  
346 vascular endothelial cells to blood.

347 vWF monomers contain complex N-glycan and O-glycan structures (Ward et al., 2019). Glycan  
348 determinants play critical roles in regulating multiple aspects of vWF biology. Importantly, the vWF  
349 synthesized in endothelial cells is fully sialylated, whereas platelet-derived vWF has been shown  
350 to have significantly reduced vWF N-linked sialylation, which regulates proteolysis by ADAMTS13  
351 (Mcgrath et al., 2013). Loss of sialic acid from glycans in the extremity in vWF terminates with Gal  
352 or GalNAc residues. Gal residues trigger enhanced vWF clearance through several different  
353 pathways, including the asialoglycoprotein receptor (ASGPR; also known as Ashwell-Morell  
354 receptor) on hepatocytes or macrophage galactose lectin receptor (MGL) on macrophages  
355 (Aguila et al., 2019). Thus, stabilizing vWF in blood to cover terminal sialic acid residues is  
356 important, leading to blood vessel formation, homeostasis, and repair after injury.

357 Finally, since MDD is a clinically heterogeneous phenotype, they are occasionally misdiagnosed  
358 at the expense of other mental disorders, such as bipolar disorder and schizophrenia (Mitchell et  
359 al., 2009). A comprehensive differential diagnosis of MDD is necessary for the clinical follow-up  
360 to distinguish the disorder from other mental conditions. Interestingly, the expression level of vWF  
361 in human plasma significantly increased in patients with bipolar disorder and schizophrenia  
362 compared to healthy subjects, with no differences between the two diagnostic groups (Hope et  
363 al., 2009). Endothelial hyperactivation is inferred to be an essential mechanism for the  
364 pathophysiology of bipolar disorder and schizophrenia. We showed that the low levels of vWF in  
365 plasma EVs in patients with MDD in depressive state have the potential for different  
366 characteristics from other mental disorders, leading to a rigorous tool for the clinical diagnosis of



367 MDD. The blood-derived biomarker we found will contribute to the comprehensive diagnosis of  
368 MDD in addition to the psychological tests and the diagnostic imaging.

369 In summary, this study extensively screened the glycosylation patterns and glycoproteins  
370 expressed in plasma EVs from patients with MDD, and we identified sialylated vWF. This finding  
371 reveals not only a novel biomarker of MDD status but also original insight into the pathogenesis  
372 of MDD caused by endothelial dysfunction, which may provide novel approaches for MDD  
373 treatment.

374

### 375 **Supplementary Materials**

#### 376 **Supplementary Figures:**

377 Fig. S1. Lectin array data of human leukocytes in healthy subjects (HS), patients with MDD in  
378 depressive (DP) or remission state (REM).

379 Fig. S2. Identification of vWF as a protein recognized by WGA.

380 Fig. S3. No significant differences for vWF levels in human plasma were found between patients  
381 with MDD and healthy subjects.

382 Fig. S4. Standard curve for a sandwich WGA-vWF ELISA.

#### 383 **Supplementary Tables:**

384 Table S1. Demographics and clinical characteristics of study participants.

385 Table S2. Lectins used for detection of glycosylation of EVs.

386

### 387 **Acknowledgements**



388 We thank participants and their generously volunteered time. We thank T. Matsubara, F. Higuchi,  
389 K. Harada, M. Masaaki for support with clinical protocol, patient care, or collection and provision  
390 of patient samples. We thank the Yamaguchi University Center for Gene Research for assistance  
391 with nanoparticle tracking analysis.

392

### 393 **Fundings**

394 This research was supported partly by Japan Agency for Medical Research and Development  
395 (grant number 22dk0307103h0002) and the the Strategic Research Program for Brain Sciences  
396 (Integrated Research on Neuropsychiatric Disorders). K.T. received support from SENSHIN  
397 Medical Research Foundation, Japan and The Finding-Out & Crystallization of Subliminals  
398 (FOCS) project by the Yamaguchi University of Medicine. This work was also the result of using  
399 program for supporting construction of core facilities in MEXT Project for promoting public  
400 utilization of advanced research infrastructure (grant number JPMXS0440400023).

401

### 402 **Author contributions**

403 N.Y., K.T., N.T. and S.N. conceived and designed the study. N.Y., K.T., C.N. and A.K performed  
404 experiments. N.Y. and K.T. did the data analysis and interpretation. N.Y., Y.M. and S.N. provided  
405 the clinical data and selected samples in this study. A.K. and S.N. did blood sample collection.  
406 Y.M. did transmission electron microscopy analysis. H.Y. did initial assay development and  
407 provided the lectin array data of human plasma. N.T. provided the technic and the knowledge in  
408 EV analyzing. N.Y., K.T., N.T. and S.N. wrote the manuscript and prepared the figures. All authors  
409 reviewed and edited the paper.

410

411 **Declaration of Interest:** The authors declare no competing financial interests.

412 **Data and materials availability:** All data in this published article (and its Supplementary  
413 Information files) are available. The other data analyzed in the current study are not publicly  
414 available for ethical reasons.

415

## 416 **References**

417 Aguila S, Lavin M, Dalton N, Patmore S, Chion A, Trahan GD, Jones KL, Keenan C, Brophy TM,  
418 O'connell NM, et al (2019) Increased galactose expression and enhanced clearance in patients  
419 with low von Willebrand factor

420 B. Boneu, M. Abbal, J. Plante & R. Bierme (1975) FACTOR-VIII COMPLEX AND ENDOTHELIAL  
421 DAMAGE

422 Baganz NL & Blakely RD (2013) A dialogue between the immune system and brain, spoken in  
423 the language of serotonin. ACS Chem Neurosci 4: 48–63 doi:10.1021/cn300186b [PREPRINT]

424 Bockenstedt P, Greenberg JM & Handin RI (1986) Structural basis of von Willebrand factor  
425 binding to platelet glycoprotein Ib and collagen. Effects of disulfide reduction and limited  
426 proteolysis of polymeric von Willebrand factor. Journal of Clinical Investigation 77: 743–749

427 Boeck C, Pfister S, Bürkle A, Vanhooren V, Libert C, Salinas-Manrique J, Dietrich DE, Kolassa IT  
428 & Karabatsiakos A (2018) Alterations of the serum N-glycan profile in female patients with Major  
429 Depressive Disorder. J Affect Disord 234: 139–147

430 Bonazza K, Iacob RE, Hudson NE, Li J, Lu C, Engen JR & Springer TA (2022) Von Willebrand  
431 factor A1 domain stability and affinity for GPIIb $\alpha$  are differentially regulated by its O-glycosylated  
432 N-and C-linker. Elife 11

433 Casonato A, Daidone V, Sartorello F, Albiger N, Romualdi C, Mantero F, Pagnan A & Scaroni C  
434 (2008) Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-

- 435 induced increase in von Willebrand factor: The lesson learned from Cushing syndrome. *Br J*  
436 *Haematol* 140: 230–235
- 437 Delpech JC, Herron S, Botros MB & Ikezu T (2019) Neuroimmune Crosstalk through Extracellular  
438 Vesicles in Health and Disease. *Trends Neurosci* 42: 361–372 doi:10.1016/j.tins.2019.02.007  
439 [PREPRINT]
- 440 Denorme F, Vanhoorelbeke K & De Meyer SF (2019) von Willebrand Factor and Platelet  
441 Glycoprotein Ib: A Thromboinflammatory Axis in Stroke. *Front Immunol* 10  
442 doi:10.3389/fimmu.2019.02884 [PREPRINT]
- 443 Escrevente C, Keller S, Altevogt P & Costa J (2011) Interaction and uptake of exosomes by  
444 ovarian cancer cells. *BMC Cancer* 11
- 445 Folstein MF, Folstein SE & Mchugh PR (1975) 'MINI-MENTAL STATE' A PRACTICAL METHOD  
446 FOR GRADING THE COGNITIVE STATE OF PATIENTS FOR THE CLINICIAN\* Pergamon  
447 Press
- 448 Gelle T, Samey RA, Plansont B, Bessette B, Jauberteau-Marchan MO, Lalloué F & Girard M  
449 (2021) BDNF and pro-BDNF in serum and exosomes in major depression: Evolution after  
450 antidepressant treatment. *Prog Neuropsychopharmacol Biol Psychiatry* 109
- 451 Goetzl EJ, Wolkowitz OM, Srihari VH, Reus VI, Goetzl L, Kapogiannis D, Heninger GR & Mellon  
452 SH (2021) Abnormal levels of mitochondrial proteins in plasma neuronal extracellular vesicles  
453 in major depressive disorder. *Mol Psychiatry* 26: 7355–7362
- 454 Gogia S & Neelamegham S (2015) Role of fluid shear stress in regulating VWF structure, function  
455 and related blood disorders. *Biorheology* 52: 319–335 doi:10.3233/BIR-15061 [PREPRINT]
- 456 HAMILTON M (1960) A rating scale for depression. *J Neurol Neurosurg Psychiatry* 23: 56–62


- 457 Herrman H, Kieling C, McGorry P, Horton R, Sargent J & Patel V (2019) Reducing the global  
458 burden of depression: a Lancet–World Psychiatric Association Commission. *The Lancet* 393:  
459 e42–e43 doi:10.1016/S0140-6736(18)32408-5 [PREPRINT]
- 460 Hope S, Melle I, Aukrust P, Steen NE, Birkenaes AB, Lorentzen S, Agartz I, Ueland T &  
461 Andreassen OA (2009) Similar immune profile in bipolar disorder and schizophrenia: Selective  
462 increase in soluble tumor necrosis factor receptor I and von Willebrand factor. *Bipolar Disord*  
463 11: 726–734
- 464 Hung YY, Chou CK, Yang YC, Fu HC, Loh EW & Kang HY (2021) Exosomal let-7e, mir-21-5p,  
465 mir-145, mir-146a and mir-155 in predicting antidepressants response in patients with major  
466 depressive disorder. *Biomedicines* 9
- 467 Ignácio ZM, da Silva RS, Plissari ME, Quevedo J & Réus GZ (2019) Physical Exercise and  
468 Neuroinflammation in Major Depressive Disorder. *Mol Neurobiol* 56: 8323–8335  
469 doi:10.1007/s12035-019-01670-1 [PREPRINT]
- 470 Ju L, Chen Y, Zhou F, Lu H, Cruz MA & Zhu C (2015) Von Willebrand factor-A1 domain binds  
471 platelet glycoprotein Iba in multiple states with distinctive force-dependent dissociation kinetics.  
472 *Thromb Res* 136: 606–612
- 473 Leebeek FWG & Eikenboom JCJ (2016) Von Willebrand’s Disease. *New England Journal of*  
474 *Medicine* 375: 2067–2080
- 475 Li L Di, Naveed M, Du ZW, Ding H, Gu K, Wei LL, Zhou YP, Meng F, Wang C, Han F, et al (2021)  
476 Abnormal expression profile of plasma-derived exosomal microRNAs in patients with  
477 treatment-resistant depression. *Hum Genomics* 15
- 478 Li Y, Li L, Dong F, Guo L, Hou Y, Hu H, Yan S, Zhou X, Liao L, Allen TD, et al (2015) Plasma von  
479 Willebrand factor level is transiently elevated in a rat model of acute myocardial infarction. *Exp*  
480 *Ther Med* 10: 1743–1749

- 481 Malhi GS & Mann JJ (2018) Depression. *The Lancet* 392: 2299–2312 doi:10.1016/S0140-  
482 6736(18)31948-2 [PREPRINT]
- 483 Mcgrath RT, Van Den Biggelaar M, Byrne B, O’sullivan JM, Rawley O, O’kennedy R, Voorberg J,  
484 Preston RJS & O’donnell JS (2013) Altered glycosylation of platelet-derived von Willebrand  
485 factor confers resistance to ADAMTS13 proteolysis.
- 486 Mitchell AJ, Vaze A & Rao S (2009) Clinical diagnosis of depression in primary care: a meta-  
487 analysis. [www.thelancet.com](http://www.thelancet.com) 374
- 488 Moos RH, McCoy L & Moos BS (2000) Global Assessment of Functioning (GAF) ratings:  
489 Determinants and role as predictors of one-year treatment outcomes. *J Clin Psychol* 56: 449–  
490 461
- 491 Nasca C, Dobbin J, Bigio B, Watson K, de Angelis P, Kautz M, Cochran A, Mathé AA, Kocsis JH,  
492 Lee FS, et al (2021) Insulin receptor substrate in brain-enriched exosomes in subjects with  
493 major depression: on the path of creation of biosignatures of central insulin resistance. *Mol*  
494 *Psychiatry* 26: 5140–5149
- 495 Nishida-Aoki N, Tominaga N, Kosaka N & Ochiya T (2020) Altered biodistribution of  
496 deglycosylated extracellular vesicles through enhanced cellular uptake. *J Extracell Vesicles* 9
- 497 Norman M, Ter-Ovanesyan D, Trieu W, Lazarovits R, Kowal EJK, Lee JH, Chen-Plotkin AS,  
498 Regev A, Church GM & Walt DR (2021) L1CAM is not associated with extracellular vesicles in  
499 human cerebrospinal fluid or plasma. *Nat Methods* 18: 631–634
- 500 Ohtsubo K & Marth JD (2006) Glycosylation in Cellular Mechanisms of Health and Disease. *Cell*  
501 126: 855–867 doi:10.1016/j.cell.2006.08.019 [PREPRINT]
- 502 Otsubo T, Tanaka K, Koda R, Shinoda J, Sano N, Tanaka S, Aoyama H, Mimura M & Kamijima  
503 K (2005) Reliability and validity of Japanese version of the Mini-International Neuropsychiatric  
504 Interview. *Psychiatry Clin Neurosci* 59: 517–526

- 505 Park DI, Štambuk J, Razdorov G, Pučić-Baković M, Martins-De-Souza D, Lauc G & Turck CW  
506 (2018) Blood plasma/IgG N-glycome biosignatures associated with major depressive disorder  
507 symptom severity and the antidepressant response. *Sci Rep* 8
- 508 Peyvandi F, Garagiola I & Baronciani L (2011) Role of von Willebrand factor in the haemostasis.  
509 *Blood Transfusion* 9 doi:10.2450/2011.002S [PREPRINT]
- 510 Recasens M, Almolda B, Pérez-Clausell J, Campbell IL, González B & Castellano B (2021)  
511 Chronic exposure to IL-6 induces a desensitized phenotype of the microglia. *J*  
512 *Neuroinflammation* 18
- 513 Sabbagh Q, André-Grégoire G, Alves-Nicolau C, Dupont A, Bidère N, Jouglar E, Guével L, Frénel  
514 JS & Gavard J (2021) The von Willebrand factor stamps plasmatic extracellular vesicles from  
515 glioblastoma patients. *Sci Rep* 11
- 516 Saeedi S, Israel S, Nagy C & Turecki G (2019) The emerging role of exosomes in mental disorders.  
517 *Transl Psychiatry* 9 doi:10.1038/s41398-019-0459-9 [PREPRINT]
- 518 Saeedi S, Nagy C, Ibrahim P, Thérroux JF, Wakid M, Fiori LM, Yang J, Rotzinger S, Foster JA,  
519 Mechawar N, et al (2021) Neuron-derived extracellular vesicles enriched from plasma show  
520 altered size and miRNA cargo as a function of antidepressant drug response. *Mol Psychiatry*  
521 26: 7417–7424
- 522 Smith SM & Vale WW (2006) The role of the hypothalamic-pituitary-adrenal axis in  
523 neuroendocrine responses to stress
- 524 Steinmetz CC & Turrigiano GG (2010) Tumor necrosis factor- $\alpha$  signaling maintains the ability of  
525 cortical synapses to express synaptic scaling. *Journal of Neuroscience* 30: 14685–14690
- 526 Streetley J, Fonseca A-V, Turner J, Kiskin NI, Knipe L, Rosenthal PB & Carter T (2019) Stimulated  
527 release of intraluminal vesicles from Weibel-Palade bodies


- 528 Tominaga N (2021) Anti-cancer role and therapeutic potential of extracellular vesicles. *Cancers*  
529 (Basel) 13 doi:10.3390/cancers13246303 [PREPRINT]
- 530 Uddin M, Koenen KC, Aiello AE, Wildman DE, De Los Santos R & Galea S (2011) Epigenetic and  
531 inflammatory marker profiles associated with depression in a community-based epidemiologic  
532 sample. *Psychol Med* 41: 997–1007
- 533 Valentijn KM, Valentijn JA, Jansen KA & Koster AJ (2008) A new look at Weibel-Palade body  
534 structure in endothelial cells using electron tomography. *J Struct Biol* 161: 447–458
- 535 Ward S, O’Sullivan JM & O’Donnell JS (2019) von Willebrand factor sialylation—A critical  
536 regulator of biological function. *Journal of Thrombosis and Haemostasis* 17: 1018–1029  
537 doi:10.1111/jth.14471 [PREPRINT]
- 538 Wu WC, Song SJ, Zhang Y & Li X (2020) Role of Extracellular Vesicles in Autoimmune  
539 Pathogenesis. *Front Immunol* 11 doi:10.3389/fimmu.2020.579043 [PREPRINT]
- 540 Xu R, Greening DW, Zhu HJ, Takahashi N & Simpson RJ (2016) Extracellular vesicle isolation  
541 and characterization: Toward clinical application. *Journal of Clinical Investigation* 126: 1152–  
542 1162 doi:10.1172/JCI81129 [PREPRINT]
- 543 Yamagata H, Uchida S, Matsuo K, Harada K, Kobayashi A, Nakashima M, Higuchi F, Watanuki  
544 T, Matsubara T & Watanabe Y (2018) Altered plasma protein glycosylation in a mouse model  
545 of depression and in patients with major depression. *J Affect Disord* 233: 79–85
- 546 Zhu C Bin, Blakely RD & Hewlett WA (2006) The proinflammatory cytokines interleukin-1beta and  
547 tumor necrosis factor-alpha activate serotonin transporters. *Neuropsychopharmacology* 31:  
548 2121–2131
- 551

## Figures




**Fig. 1. Overview of experimental framework for EVs enrichment and extraction by size-exclusion chromatography.** We purified EVs from the plasma of healthy subjects (HS, n = 20) or patients with major depressive disorder (MDD, n = 21) by centrifugations, filtration, and passing through size-exclusion chromatography (SEC). The BCA protein assay and western blotting show a typical elution profile of plasma EVs obtained from a healthy subject.






**Fig. 2. Efficient separation of EVs in plasma obtained from HS, DP, and REM by size exclusion chromatography.** (A) Representative western blotting using plasma EVs in HS, patients with MDD in depressive state (DP), and remission state (REM) to confirm EVs-enriched fractions. We assessed protein extracts (400 ng) from cells or EVs using antibodies against EV protein markers (CD63, CD9) and a mitochondrial protein marker (cytochrome c (Cyt c)). We used protein extracts of HEK293T cells (Cell) to distinguish EVs from cells. (B) Representative photomicrographs of EVs isolated from plasma in HS, DP, or REM imaged by CryoEM. Scale bar: 100 nm. (C) Representative particle size histogram of EVs in the enriched plasma fractions in HS, DP, or REM by NTA. (D) Box plot of size, particle concentration, and protein concentration in plasma EVs after SEC. Each dot presents one sample. HS; n = 20, MDD: n = 21. (E) Paired box plots depicting individual patient data between patients with MDD (n = 10) in DP and REM in size, particle concentration, and protein concentration. We used Mann - Whitney U test or Student t-test to test for significance. \*  $p < 0.05$ , n.s. nonsignificant.




**Fig. 3. WGA lectin detects changes in the glycosylation status in plasma EVs in HS, MDD, and REM.** (A) O-glycan profiling of plasma EVs of HS and DP by lectin blotting. We detected glycosyl chains by biotinylated lectins followed by HRP-conjugated streptavidin. Lectins used for detections: UEA-I, PNA, and DBA. We loaded same amount of protein concentration (400 ng/lane). (B) N-glycomic profiling of plasma EVs of HS and DP by lectin blotting. Lectins used for detections: SBA, ConA, RCA120, and WGA. We loaded same amount of protein concentration (400 ng/lane). The red line indicates bands at approximately 250 kDa. (C) we analyzed relative

intensity in arbitrary units by Image J in (B). The number of independent: HS; n = 5, DP; n = 5. **(D)** The boxplots represent the signal intensity of protein bands in arbitrary units. **(E)** Receiver operating characteristic (ROC) curve analysis using the intensity of WGA lectin in plasma EVs to diagnose HS or MDD. A cutoff value is 2450 by the closest-top-left method. **(F)** Lectin blotting profiles detected by WGA in plasma EVs from patients with MDD in DP and REM. We used plasma EVs by HS as a positive control. The red line indicates bands at approximately 250 kDa. **(G)** Paired box plots depicting individual patient data between patients with MDD (n = 10) in DP and REM. **(H)** ROC curve analysis of intensity of WGA as a biomarker of DP compared with REM. A cutoff value is 2130 by the closest-top-left method. We used Mann - Whitney U test or Student t-test to test for significance. \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , n.s. nonsignificant.



**Fig. 4. Proteome analysis revealed that vWF in plasma EVs related to the stage of MDD.** (A) SDS-PAGE gel with silver staining. The gels contain protein standard (lane 1) and HS (lane 2 - 4). Coverage of above 250kDa protein (red dashed line) in plasma EV obtained HS analyzed by LC-MS. (B) List of polypeptides within above 250kDa protein identified in the proteomics analysis. (C) Representative image of western blotting for vWF protein (Molecular weight, 260 kDa) in plasma EVs (400 ng) obtained from HS (n = 5), patients with MDD in DP (n = 5). (D) Representative image of western blotting for plasma EVs proteins (400 ng) in HS (n = 5) with or without sialidase (SA) treatment. We detected the PVDF membrane strips with an antibody against vWF. (E) Densitometric measurement of vWF antigen (Ag) in plasma EVs from HS (n = 20) and MDD (n = 21) by sandwich ELISA. The absorbance read at 450 nm. (F) ROC curve analysis using vWF Ag in plasma EVs for diagnosis of MDD. A cutoff value is 0.276  $\mu\text{g/mL}$  by the closest-top-left method. (G) Paired box plots depicting individual patient data between patients with MDD (n = 10) in DP and REM. (H) ROC curve analysis using vWF Ag in plasma EVs for diagnosis of MDD. A cutoff value is 0.606  $\mu\text{g/mL}$  by the closest-top-left method. We used Mann - Whitney U test or Student t-test to test for significance. \*\*  $p < 0.01$ .



**Fig. 5. The levels of vWF Ag recognized by WGA in plasma EVs strongly correlate with the depressive state.** (A) The scheme of lectin-antibody sandwich ELISA for quantification of WGA-vWF protein. Bound vWF antibodies after PNGase treatment were detected using HRP-conjugated WGA lectin. The absorbance read at 450 nm. (B) Normalized absorbance of WGA-vWF antigen (Ag) in plasma EVs (1 µg protein each sample) in healthy subjects (n = 8) with or without SA treatment by the lectin-antibody sandwich ELISA. The level of vWF recognized by WGA showed significant changes due to the desialylation of vWF. (C) Quantification of WGA-vWF: Ag in plasma EVs by ELISA between patients with MDD (n = 21) and HS (n = 20). (D) ROC curve analysis of the concentration of WGA-vWF: Ag in plasma EVs for diagnosis of MDD in depressive state. The cutoff value is 0.129 µg/mL by the closest-top-left method. (E) Paired box plots depicting individual patient data of WGA-vWF: Ag in plasma EVs between patients with MDD (n = 10) in DP and REM. (F) ROC curve analysis of WGA-vWF: Ag in plasma EVs between DP and REM in the same patients with MDD. A cutoff value is 0.053 µg/mL by the closest-top-left method. We used Mann - Whitney U test or Student t-test to test for significance. \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .